Beschreibung
Combining rivaroxaban with clopidogrel substantially increases bleeding risk through simultaneous inhibition of factor Xa and platelet P2Y12 receptors.
Mechanismus
Rivaroxaban inhibits factor Xa, preventing thrombin generation and fibrin clot formation; clopidogrel irreversibly blocks ADP-mediated platelet activation. The combined antithrombotic burden is greater than either alone.
Klinische Bedeutung
Clinical trial data (PIONEER AF-PCI) demonstrate significantly higher bleeding rates with this combination, particularly GI hemorrhage.
Maßnahmen
Minimize duration of dual therapy to the lowest risk-stratified period; add gastroprotection; reassess at each visit whether both agents are still needed.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.